Here’s the GSK dividend forecast for 2023 and 2024!

The GSK share price offers solid all-round value for money right now. Should investors buy the FTSE firm based on current dividend forecasts?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Young black man looking at phone while on the London Overground

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Based on current dividend forecasts, pharmaceuticals giant GSK (LSE:GSK) could be a good choice for passive income investors.

At £14.37 per share, the GSK share price carries a 3.9% dividend yield for 2023. This is higher than the 3.6% average for FTSE 100 shares.

And things get even better for next year. For then, the healthcare giant’s dividend yield marches to 4.2%.

So should investors buy GSK shares to make a healthy second income? Or would buying other UK dividend shares be a better idea?

Dividend growth

To recap, dividends at the drugs developer fell in 2022 to 57.75p per share, from 80p in previous years. This reflected the company’s desire to boost investment in R&D and give it more firepower for acquisitions.

But City brokers expect dividends to start rising straight away. GSK has said it plans to raise the annual dividend to 56.5p per share in 2023, a target that brokers think is likely. Furthermore, analysts expect the full-year payout will increase again to 59.9p next year.

This results in those market-beating yields. And what’s more, current profits forecasts suggest the pharma giant will be in good shape to meet those payout targets.

Predicted dividends for the period are covered 2.6 times. Dividend coverage above 2 times provides a wide margin of safety to investors.

On the right track

Impressive first-quarter numbers suggest GSK could be good shape to grow earnings and dividends. Excluding the sale of Covid-19 products, turnover rose by 10% in the first quarter, thanks to strong demand for its shingles and HIV treatments.

The huge sums GSK’s ploughing into R&D mean the firm is set it up well to find the next blockbuster treatment and grow earnings strongly. As of March, it had a healthy 68 vaccine and speciality medicines in its development pipeline.

There’s no guarantee that these treatments will see the light of day, of course. Medicine development can be highly unpredictable and disappointments at the testing and regulatory stages are common. But the FTSE company’s packed pipeline gives it a terrific chance to find the next profits driver.

These include Daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that’s used to treat anaemia in chronic kidney disease patients. Sales of these drugs are expected to grow into the billions over the next several years. And GSK will have the only HIF-PHI on the market in the US when it likely launches later this year.

On top of this, GSK now has the financial clout to search out the next major sales booster through steady acquisition activity. This month, it snapped up Bellus Health, a company whose chronic cough treatment Camlipixant has been described by GSK as potentially best-in-class.

The verdict

Buying healthcare shares could be a lucrative way to make long-term returns. A growing global population, allied with soaring healthcare spending in emerging markets, bodes well for drugs developers.

As a fan of value stocks, I think GSK shares are especially attractive right now. On top of those large dividend yields, its shares trade on a forward price-to-earnings (P/E) ratio of just 9.8 times.

With its drug development programmes making strong progress I think now could be a great time to invest.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

1 no-brainer pick I’d love to buy for my Stocks & Shares ISA!

A Stocks & Shares ISA is a great investment vehicle for our writer. Here she explains why, and one stock…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Just released: our 3 best dividend-focused stocks to buy before May [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Will the Rolls-Royce share price keep rising in 2024?

With the Rolls-Royce share price going on a surge, this Fool wants to look forward to where it could potentially…

Read more »

Investing Articles

£10k in an ISA? Here’s how I’d target a regular £30k+ second income stream

Reliable dividends can help provide a lot more financial freedom. Here's how I'd aim for a substantial second income inside…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Lloyds share price hanging on to 50p ahead of Wednesday’s Q1 earnings report. Where to now?

Down in April and with low earnings expected this week, Mark David Hartley investigates where the Lloyds share price might…

Read more »

artificial intelligence investing algorithms
Investing Articles

Everyone’s talking about AI! Here’s 1 FTSE stock to consider buying for exposure

A hot topic right now is artificial intelligence (AI). This Fool explains how this FTSE stock could offer investors an…

Read more »

British Pennies on a Pound Note
Investing Articles

1 penny stock I’d buy today while it is 99p

Ben McPoland highlights Windward (AIM:WNWD), a fast-growing penny stock that could benefit from the artificial intelligence revolution.

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

This forgotten FTSE 100 gem could be the best bargain on the stock market

The FTSE 100 is full to the brim of high-quality businesses. But this Fool has his eye on this 'forgotten'…

Read more »